



Cancer Clinical Trials in Hawai'i

University of Hawai'i Cancer Center

An NCI-Designated Cancer Center



Mission Statement

To reduce the burden of cancer for the people of Hawai'i and the Pacific by providing access to innovative clinical trials


Translational & Clinical Research Services

- Scientific Review of National, Industry and Investigator-Initiated protocols (Protocol Review & Monitoring Committee [PRMC])
- Protection of research subjects from unnecessary risks (Quality Assurance Program and Data Safety & Monitoring Committee [DSMC])
- Promotion of protocols to community-based cancer care providers
- Community outreach to increase participation of underserved, high-risk groups to therapeutic, prevention, screening and observational trials
- Mentorship and support of investigators in developing investigator-initiated translational research protocols


Clinical Trials Office (CTO)

- Robust infrastructure to support NCI Cooperative Group, Industry and Investigator-initiated trials across the State of Hawai'i
- Clinical Protocol and Data Management (OnCore)
- Ongoing training of clinical research personnel (UHCC-based and through the Society of Clinical Research Associates)
- Contracting and regulatory affairs support for all trials

2017 Enrollment by Race/Ethnicity to Clinical Trials



Clinical Trials Network



Future Directions

- Expand UH Cancer Center's leadership role to enhance accrual to all types of clinical trials throughout the State to improve quality of care and outcomes
- Translate discoveries derived from UH Cancer Center research into clinical trials
- Reduce cancer health disparities through community outreach, education and research targeted to disadvantaged populations
- Expand access to early phase trials through development of a Phase I program
- Continue recruitment of experienced academic physician investigators
- Continue to explore relationships between genetics, environment, obesity and lifestyle to the development of cancer in order to develop targeted cancer prevention programs

Accomplishments

- One of only 70 NCI-designated cancer centers in nation to provide patients in Hawai'i access to cutting edge, novel approaches for cancer treatment, diagnosis and prevention
- Robust enrollment of racial and ethnic minorities to clinical trials to address cancer health disparities
- Major contributor to national Cancer Care Delivery Research (CCDR) studies
- Enroll nearly 200 patients/year to clinical trials across the UH Cancer Center clinical trials network
- American Society of Clinical Oncology (ASCO) Clinical Trials Participation Award Honoree (May 2009)
- Awarded MB-CCOP (Minority-Based Community Clinical Oncology Program) grant in June 1994 with renewal every five years through August 2014
- Awarded NCORP (NCI Community Oncology Research Program) grant in August 2014 with renewal in 2019
- Recruitment of disease-focused oncology specialists

Key Personnel

Associate Director for Translational and Clinical Research: Charles Rosser, MD, MBA
Medical Director, CTO: Jessica Rhee, MD, MS
Chair PRMC: Jeffrey Berenberg, MD
Chair DSMC: Jonathan Cho, MD
Chair Community Research Advocacy Board: Jared Acoba, MD
Investigator-initiated Trials Lead: Jeffrey Huang, PharmD
CTO Clinical Manager: Kate Bryant-Greenwood, JD, MA, CCRP
CTO Assist. Clinical Manager: Virginia McMahon, BA, CCRP